IL162353A0 - Combination of cytochrome p450 dependent protease inhibitors - Google Patents
Combination of cytochrome p450 dependent protease inhibitorsInfo
- Publication number
- IL162353A0 IL162353A0 IL16235302A IL16235302A IL162353A0 IL 162353 A0 IL162353 A0 IL 162353A0 IL 16235302 A IL16235302 A IL 16235302A IL 16235302 A IL16235302 A IL 16235302A IL 162353 A0 IL162353 A0 IL 162353A0
- Authority
- IL
- Israel
- Prior art keywords
- cytochrome
- combination
- protease inhibitors
- dependent protease
- dependent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01204841 | 2001-12-12 | ||
| PCT/EP2002/014277 WO2003049746A2 (en) | 2001-12-12 | 2002-12-12 | Combination of cytochome p450 dependent protease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL162353A0 true IL162353A0 (en) | 2005-11-20 |
Family
ID=8181408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16235302A IL162353A0 (en) | 2001-12-12 | 2002-12-12 | Combination of cytochrome p450 dependent protease inhibitors |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20050119338A1 (xx) |
| EP (1) | EP1458447B1 (xx) |
| JP (1) | JP2005511723A (xx) |
| KR (1) | KR100974921B1 (xx) |
| CN (1) | CN100335060C (xx) |
| AR (1) | AR037797A1 (xx) |
| AT (1) | ATE442189T1 (xx) |
| AU (1) | AU2002358713B2 (xx) |
| BR (1) | BR0215043A (xx) |
| CA (1) | CA2469343C (xx) |
| CY (1) | CY1110604T1 (xx) |
| DE (1) | DE60233677D1 (xx) |
| DK (1) | DK1458447T3 (xx) |
| ES (1) | ES2333206T3 (xx) |
| HK (1) | HK1070008A1 (xx) |
| HR (1) | HRP20040619A2 (xx) |
| HU (1) | HUP0402644A3 (xx) |
| IL (1) | IL162353A0 (xx) |
| MX (1) | MXPA04005755A (xx) |
| NO (1) | NO20042666L (xx) |
| NZ (1) | NZ533826A (xx) |
| PL (1) | PL373072A1 (xx) |
| PT (1) | PT1458447E (xx) |
| RU (1) | RU2329050C2 (xx) |
| SI (1) | SI1458447T1 (xx) |
| TW (1) | TWI286476B (xx) |
| WO (1) | WO2003049746A2 (xx) |
| ZA (1) | ZA200404633B (xx) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0414916A (pt) * | 2003-09-30 | 2006-11-07 | Tibotec Pharm Ltd | métodos para a preparação de compostos de sulfonamida de benzoxazol e intermediários dos mesmos |
| EP1715847A1 (en) * | 2003-12-23 | 2006-11-02 | Tibotec Pharmaceuticals Ltd. | Self-microemulsifying drug delivery systems of a hiv protease inhibitor6 |
| CA2566340C (en) * | 2004-05-07 | 2014-05-06 | Sequoia Pharmaceuticals, Inc. | Resistance-repellent retroviral protease inhibitors |
| DE602005009366D1 (de) * | 2004-07-08 | 2008-10-09 | Tibotec Pharm Ltd | Kombination aus tenofovir, ritonavir und tmc114 |
| BRPI0607827B8 (pt) | 2005-02-25 | 2021-05-25 | Janssen R & D Ireland | composto precursor de inibidor de protease, processo para a produção do referido composto e seu uso |
| US20070003608A1 (en) * | 2005-04-08 | 2007-01-04 | Almond Merrick R | Compounds, compositions and methods for the treatment of viral infections and other medical disorders |
| AR053845A1 (es) * | 2005-04-15 | 2007-05-23 | Tibotec Pharm Ltd | 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450 |
| TWI385173B (zh) * | 2005-11-28 | 2013-02-11 | Tibotec Pharm Ltd | 作為ｈｉｖ蛋白酶抑制劑之經取代的胺基苯基磺醯胺化合物 |
| TWI432438B (zh) * | 2005-11-28 | 2014-04-01 | Tibotec Pharm Ltd | 作為ｈｉｖ蛋白酶抑制劑之經取代的胺基苯基磺醯胺化合物及衍生物 |
| SG170796A1 (en) * | 2005-12-30 | 2011-05-30 | Gilead Sciences Inc Us | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| JO2841B1 (en) * | 2006-06-23 | 2014-09-15 | تيبوتيك فارماسيوتيكالز ليمتد | 2-(substituted-amino) -benzothiazole sulfonamide as protease inhibitors HIV (HIV) |
| AU2007285759B2 (en) | 2006-08-18 | 2013-11-21 | Sequoia Pharmaceuticals, Inc. | Compositions and methods for inhibiting cytochrome P450 |
| CN101702908A (zh) * | 2007-03-23 | 2010-05-05 | 麻萨诸塞州大学 | Hiv-1蛋白酶抑制剂 |
| UA103013C2 (uk) | 2007-12-06 | 2013-09-10 | Тиботек Фармасьютикелз | Амідні сполуки як активатори противірусних препаратів |
| PA8809601A1 (es) * | 2007-12-24 | 2009-07-23 | Cipla Ltd | Combinación anti-retroviral |
| US8993542B2 (en) | 2008-01-25 | 2015-03-31 | Chimerix Inc. | Methods of treating viral infections |
| BRPI0920809A2 (pt) | 2008-10-07 | 2016-07-12 | Tibotec Pharm Ltd | compostos de amida como reforcos de antivirais |
| WO2010132494A1 (en) | 2009-05-11 | 2010-11-18 | Ghosh Arun K | Compounds and methods for treating aids and hiv infections |
| JO3090B1 (ar) * | 2009-12-11 | 2017-03-15 | Janssen Sciences Ireland Uc | 5- امينو-4- هيدروكسي-بنتويل اميدات |
| US9006218B2 (en) | 2010-02-12 | 2015-04-14 | Chimerix Inc. | Nucleoside phosphonate salts |
| AU2011248620B2 (en) | 2010-04-26 | 2015-11-26 | Chimerix, Inc. | Methods of treating retroviral infections and related dosage regimes |
| JP6088425B2 (ja) * | 2010-06-01 | 2017-03-01 | アンジオン バイオメディカ コーポレーション | チトクロームｐ４５０阻害剤およびその使用 |
| SI2729130T1 (en) | 2011-07-07 | 2018-03-30 | Janssen Sciences Ireland Uc | Combined formulations of darunavir |
| ES2598823T3 (es) | 2011-07-07 | 2017-01-30 | Janssen R&D Ireland | Formulaciones de darunavir |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995010281A1 (en) * | 1993-10-13 | 1995-04-20 | Merck & Co., Inc. | Combination therapy for hiv infection |
| US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| DE69735545T2 (de) * | 1996-08-05 | 2006-08-10 | Myriad Genetics, Inc., Salt Lake City | Verwendung von beta-blatt mimetika als protease und kinase hemmer und alshemmer eines transkriptionsfaktors |
| US6180634B1 (en) * | 1997-11-13 | 2001-01-30 | Merck & Co., Inc. | Combination therapy for the treatment of AIDS |
| US6436989B1 (en) * | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| AU4828199A (en) * | 1998-06-23 | 2000-01-10 | Board Of Trustees Of The University Of Illinois, The | Multi-drug resistant retroviral protease inhibitors and associated methods |
| DK1088098T4 (en) * | 1998-06-23 | 2015-09-14 | Us Of America Represented By The Secretary Dept Of Health And Human Services | Fitnessassay and methods for reducing HIV resistance to therapy |
| MY145265A (en) * | 1998-07-20 | 2012-01-13 | Abbott Lab | Amorphous ritonavir |
| PT1159278E (pt) * | 1999-02-12 | 2006-06-30 | Vertex Pharma | Inibidores de aspartil-protease |
| US6319946B1 (en) * | 1999-02-12 | 2001-11-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of aspartyl protease |
-
2002
- 2002-12-11 AR ARP020104805A patent/AR037797A1/es unknown
- 2002-12-11 TW TW091135882A patent/TWI286476B/zh not_active IP Right Cessation
- 2002-12-12 RU RU2004121144/15A patent/RU2329050C2/ru not_active IP Right Cessation
- 2002-12-12 DE DE60233677T patent/DE60233677D1/de not_active Expired - Lifetime
- 2002-12-12 ES ES02793018T patent/ES2333206T3/es not_active Expired - Lifetime
- 2002-12-12 KR KR1020047008830A patent/KR100974921B1/ko not_active IP Right Cessation
- 2002-12-12 AU AU2002358713A patent/AU2002358713B2/en not_active Revoked
- 2002-12-12 JP JP2003550795A patent/JP2005511723A/ja active Pending
- 2002-12-12 EP EP02793018A patent/EP1458447B1/en not_active Revoked
- 2002-12-12 CA CA002469343A patent/CA2469343C/en not_active Expired - Fee Related
- 2002-12-12 PT PT02793018T patent/PT1458447E/pt unknown
- 2002-12-12 IL IL16235302A patent/IL162353A0/xx unknown
- 2002-12-12 DK DK02793018.9T patent/DK1458447T3/da active
- 2002-12-12 BR BR0215043-3A patent/BR0215043A/pt not_active Application Discontinuation
- 2002-12-12 WO PCT/EP2002/014277 patent/WO2003049746A2/en active Application Filing
- 2002-12-12 HU HU0402644A patent/HUP0402644A3/hu unknown
- 2002-12-12 US US10/498,024 patent/US20050119338A1/en not_active Abandoned
- 2002-12-12 PL PL02373072A patent/PL373072A1/xx not_active IP Right Cessation
- 2002-12-12 CN CNB028249119A patent/CN100335060C/zh not_active Expired - Fee Related
- 2002-12-12 NZ NZ533826A patent/NZ533826A/en not_active IP Right Cessation
- 2002-12-12 SI SI200230865T patent/SI1458447T1/sl unknown
- 2002-12-12 AT AT02793018T patent/ATE442189T1/de not_active IP Right Cessation
-
2004
- 2004-06-10 ZA ZA200404633A patent/ZA200404633B/en unknown
- 2004-06-14 MX MXPA04005755A patent/MXPA04005755A/es active IP Right Grant
- 2004-06-24 NO NO20042666A patent/NO20042666L/no not_active Application Discontinuation
- 2004-07-07 HR HR20040619A patent/HRP20040619A2/hr not_active Application Discontinuation
-
2005
- 2005-03-18 HK HK05102399.8A patent/HK1070008A1/xx not_active IP Right Cessation
-
2009
- 2009-12-09 CY CY20091101283T patent/CY1110604T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL162353A0 (en) | Combination of cytochrome p450 dependent protease inhibitors | |
| GB0125445D0 (en) | Protease Inhibitors | |
| AU2002360732A8 (en) | Change inhibitors of dipeptidyl peptidase iv | |
| AU2002305926A1 (en) | Cysteine protease inhibitors | |
| AU2002256418A1 (en) | Inhibitors of bace | |
| AU2002242500A1 (en) | Cathepsin cysteine protease inhibitors | |
| SI1453852T1 (sl) | Selektivni arilgvanidinpeptidi kot inhibitorji urokinaze | |
| IL156776A0 (en) | Inhibitors of cruzipain and other cysteine proteases | |
| EP1467978A4 (en) | "COMPOUNDS THAT CONTAIN VACCINATES DRUG LIPASE, THEIR SYNTHESIS AND USE" | |
| EP1401453A4 (en) | PROTEASE INHIBITORS | |
| AU2002348465A1 (en) | Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease | |
| PL370348A1 (en) | Preparation of hiv protease inhibitors | |
| AU2002305868A1 (en) | Inhibitors of reggamma | |
| AU2002363791A1 (en) | Protease enzyme inhibitors | |
| AU2003247948A8 (en) | Cytochrome p450 genetic variations | |
| GB0109278D0 (en) | Enzyme inhibitors | |
| AU2003298035A8 (en) | Compositions and methods for inhibiting malaria protease falcipain-2 | |
| AU2003244413A8 (en) | Cytochrome p450 protein | |
| AU2002237142A1 (en) | Urokinase inhibitors | |
| ZA200305260B (en) | Inhibitors of cruzipain and other cysteine proteases. | |
| ZA200305259B (en) | Inhibitors of cruzipain and other cysteine proteases. | |
| AU2002316387A1 (en) | Nmp35 apoptosis inhibitor gene disruptions compositions and methods related thereto | |
| AU2002328906A1 (en) | Inhibitors of polyq-aggregation | |
| AU2002219398A1 (en) | Inhibitors of cruzipain and other cysteine proteases | |
| AU2002356595A1 (en) | Serin protease inhibitors |